Citigroup resumed coverage on iHuman with a new price target

BEIJING, Dec. 26, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2024.   Third Quarter 2024 Highlights Revenues were RMB239.4 million (US$34.1 million), compared with RMB261.5 million in the same period last year.Gross profit was RMB163.9 million (US$23.4 million), compared with RMB186.6 million in the same period last year.Operating income was RMB20.7 million (US$2.9 million), compare

BEIJING, Sept. 27, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenues were RMB215.1 million (US$29.6 million), compared with RMB241.0 million in the same period last year.Gross profit was RMB151.7 million (US$20.9 million), compared with RMB170.8 million in the same period last year.Operating income was RMB18.8 million (US$2.6 million), compared wi

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log i

Citigroup resumed coverage of iHuman with a rating of Buy and set a new price target of $3.10

6-K - iHuman Inc. (0001814423) (Filer)

SCHEDULE 13G/A - iHuman Inc. (0001814423) (Subject)

SCHEDULE 13G/A - iHuman Inc. (0001814423) (Subject)

BEIJING, Dec. 26, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2024.   Third Quarter 2024 Highlights Revenues were RMB239.4 million (US$34.1 million), compared with RMB261.5 million in the same period last year.Gross profit was RMB163.9 million (US$23.4 million), compared with RMB186.6 million in the same period last year.Operating income was RMB20.7 million (US$2.9 million), compare

BEIJING, Sept. 27, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenues were RMB215.1 million (US$29.6 million), compared with RMB241.0 million in the same period last year.Gross profit was RMB151.7 million (US$20.9 million), compared with RMB170.8 million in the same period last year.Operating income was RMB18.8 million (US$2.6 million), compared wi

BEIJING, June 28, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Revenues were RMB235.0 million (US$32.5 million), compared with RMB265.2 million in the same period last year.Gross profit was RMB168.1 million (US$23.3 million), compared with RMB185.6 million in the same period last year.Operating income was RMB17.5 million (US$2.4 million), compared with

SC 13G/A - iHuman Inc. (0001814423) (Subject)

SC 13G/A - iHuman Inc. (0001814423) (Subject)

SC 13G - iHuman Inc. (0001814423) (Subject)